From Frontiers Forum:
How can research translate to R&D? Or a whole new business venture? In a panel session at Science Unlimited 2019, Holtzbrinck Publishing Group CEO Stefan von Holtzbrinck, Life Biosciences CEO Mehmood Khan, Logitech CEO Bracken Darrell and EPFL’s Henry Markram discussed innovation, R&D and successful technology transfer.
Stefan von Holtzbrinck, Holtzbrinck Publishing Group
Stefan von Holtzbrinck is CEO of the family-owned Holtzbrinck Publishing Group. He has 20 years’ experience in science communication, including 3 years as MD of Nature Publishing Group. The Holtzbrinck Publishing Group has majority holdings in Springer Nature (of which Stefan is Chairman of the Supervisory Board), Digital Science, DIE ZEIT and Macmillan, and investments in Holtzbrinck Ventures, Frontiers, AMBOSS, GSV AcceleraTE and Rethink Education fund. Stefan is a member of the Executive Committee of the Max Planck Society.
Mehmood Khan, Life Biosciences
Mehmood Khan is CEO and Board Member of Life Biosciences Inc, where he provides strategic direction and operational oversight. He was previously Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo and President of Global R&D at Takeda Pharmaceuticals. Before moving into industry, Mehmood had a distinguished medical career, including as a faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit.
Bracken Darrell, Logitech
Bracken Darrell is President and CEO of Logitech, the largest Swiss consumer electronics company with CHF 3 billion in annual revenues. He is responsible for the company’s strategy for growth and profitability, for the vision for the brand as well as for the company’s operations. Logitech has been a top performer on both the Nasdaq and Swiss stock exchanges. The company value has risen by over 500 percent in the past seven years as the company has moved from PC peripherals to new categories and new brands.
Henry Markram, EPFL
Henry Markram has pioneered simulation neuroscience as a new path to understanding how the brain works. As Professor of Neuroscience at the Swiss Federal Institute of Technology in Lausanne (EPFL), he founded the Brain Mind Institute, the Blue Brain Project and the Human Brain Project, a €1 Billion European initiative to simulate the brain. His research has shifted from experimentally reverse engineering neocortical tissue to developing a software ecosystem and algorithms to convert biological data into detailed digital reconstructions of brain tissue.
Image Credit: Amanda Scott – Alias Studio Sydney
News This Week
There is no vaccine or specific treatment for COVID-19, the disease caused by the severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2. Since the outbreak began in late 2019, researchers have been racing to [...]
Corona Virus (COVID 19) Interview with Michael Osterholm an expert in infectious disease epidemiology.
Michael Osterholm is an internationally recognized expert in infectious disease epidemiology. He is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy [...]
With the new coronavirus spreading from person to person (possibly including from people without symptoms), reaching four continents, and traveling faster than SARS, driving it out of existence is looking increasingly unlikely. It’s still [...]
Wake Forest Institute for Regenerative Medicine (WFIRM) scientists have improved upon the 3D bioprinting technique they developed to engineer skeletal muscle as a potential therapy for replacing diseased or damaged muscle tissue, moving another [...]
An international team of scientists from the University of Southampton, the University of Padova, and the University of Zurich has connected a silicon neuron to a neuron from the rat hippocampus with an artificial [...]
In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of [...]
A powerful antibiotic that kills some of the most dangerous drug-resistant bacteria in the world has been discovered using artificial intelligence. The drug works in a different way to existing antibacterials and is the [...]
Artificial intelligence hit a big milestone in January — the first drug designed entirely using artificial intelligence entered human clinical trials. The compound, created by Oxford-based biotech company Exscientia, is aimed at treating obsessive-compulsive [...]
Researchers at the Massachusetts General Hospital (MGH) in the US have uncovered the ‘Achilles’ heel’ of most viruses which plague mankind, and could soon develop a universal vaccine. Vaccine research, development and testing takes [...]
Every age in the history of human civilisation has a signature material, from the Stone Age, to the Bronze and Iron Ages. We might even call today’s information-driven society the Silicon Age. Since the [...]
CRISPR gene-edited immune cells have been injected into three people with advanced cancer without any serious side effects, the first trial of its kind in the US. It is also the first CRISPR cancer [...]
“We’ll have nanobots that… connect our neocortex to a synthetic neocortex in the cloud. Our thinking will be a…. biological and non-biological hybrid.” Ray Kurzweil, TED 2014 UPDATE - February 9 2020 Since [...]
Frank Boehm (NanoApps Medical Inc. founder) and Amanda Scott (NA CEO) join NanoApps Athletics Inc. NanoApps Athletics Inc proposes a unique synergistic biochemical/nanomedical strategy for the expedited repair and healing of Achilles tendon micro [...]
In her inaugural podcast, Jamilee interviews Frank Boehm of NanoApps Medical Inc and NanoApps Athletics Inc. From Jamilee's podcast: Welcome to the first episode of "In a Click". On todays show I chat with [...]
Using straightforward chemistry and a mix-and-match, modular strategy, researchers have developed a simple approach that could produce over 65,000 different types of complex nanoparticles, each containing up to six different materials and eight segments, [...]